BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17046733)

  • 1. Impaired renal function and duration of dialysis therapy are associated with oxidative stress and proatherogenic cytokine levels in patients with end-stage renal disease.
    Pawlak K; Pawlak D; Mysliwiec M
    Clin Biochem; 2007 Jan; 40(1-2):81-5. PubMed ID: 17046733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis intensified oxidative stress, MIP-1beta and RANTES plasma levels in uraemic patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Cytokine; 2004 Dec; 28(6):197-204. PubMed ID: 15566948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating beta-chemokines and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system in hemodialyzed patients--role of oxidative stress.
    Pawlak K; Pawlak D; Mysliwiec M
    Cytokine; 2005 Jul; 31(1):18-24. PubMed ID: 15896974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cu/Zn superoxide dismutase plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease.
    Pawlak K; Pawlak D; Mysliwiec M
    Clin Biochem; 2005 Aug; 38(8):700-5. PubMed ID: 15963971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress, phosphate and creatinine levels are independently associated with vascular endothelial growth factor levels in patients with chronic renal failure.
    Pawlak K; Mysliwiec M; Pawlak D
    Cytokine; 2008 Jul; 43(1):98-101. PubMed ID: 18455421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative stress influences CC-chemokine levels in hemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Nephron Physiol; 2004; 96(4):p105-12. PubMed ID: 15122056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative stress effects fibrinolytic system in dialysis uraemic patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2006; 117(5):517-22. PubMed ID: 15964061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kynurenines and oxidative status are independently associated with thrombomodulin and von Willebrand factor levels in patients with end-stage renal disease.
    Pawlak K; Domaniewski T; Mysliwiec M; Pawlak D
    Thromb Res; 2009 Sep; 124(4):452-7. PubMed ID: 19477487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible new role of monocyte chemoattractant protein-1 in hemodialysis patients with cardiovascular disease.
    Pawlak K; Pawlak D; Mysliwiec M
    Am J Nephrol; 2004; 24(6):635-40. PubMed ID: 15627719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidative stress in elderly chronic renal failure patients: effects of renal replacement therapies on cell membrane fluidity.
    Goi G; Massaccesi L; Baquero Herrera CJ; Musetti C; Ciurlino D; Cusi D; Bertoli S
    J Nephrol; 2009; 22(5):630-6. PubMed ID: 19809996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral vitamin C supplementation in hemodialysis patients and its effect on the plasma level of oxidized ascorbic acid and Cu/Zn superoxide dismutase, an oxidative stress marker.
    Washio K; Inagaki M; Tsuji M; Morio Y; Akiyama S; Gotoh H; Gotoh T; Gotoh Y; Oguchi K
    Nephron Clin Pract; 2008; 109(2):c49-54. PubMed ID: 18544955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible association between circulating vascular endothelial growth factor and oxidative stress markers in hemodialysis patients.
    Pawlak K; Pawlak D; Myśliwiec M
    Med Sci Monit; 2006 Apr; 12(4):CR181-5. PubMed ID: 16572054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiopoietin 2 and cardiovascular disease in dialysis and kidney transplantation.
    David S; Kümpers P; Hellpap J; Horn R; Leitolf H; Haller H; Kielstein JT
    Am J Kidney Dis; 2009 May; 53(5):770-8. PubMed ID: 19268412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidative stress in chronic renal failure patients treated by peritoneal dialysis.
    Al-Hashimi AF; Mohammed FH; Al-Khazragi AS
    Saudi Med J; 2004 Sep; 25(9):1186-92. PubMed ID: 15448763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accumulation of vitamin E metabolites in the blood of renal failure patients.
    Galli F; Floridi AG; Floridi A; Buoncristiani U
    Clin Nutr; 2004 Apr; 23(2):205-12. PubMed ID: 15030960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin therapy decreased tissue factor, its pathway inhibitor, and oxidative stress in peritoneal dialysis patients with diabetes.
    Pawlak K; Pawlak D; Mysliwiec M
    Nephron Clin Pract; 2007; 107(1):c20-5. PubMed ID: 17671395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
    Lobo J; Santos F; Grosso D; Lima R; Barreira AL; Leite M; Mafra D; Abdalla DS
    Nephron Clin Pract; 2008; 108(4):c298-304. PubMed ID: 18434752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidative stress - a link between endothelial injury, coagulation activation, and atherosclerosis in haemodialysis patients.
    Pawlak K; Naumnik B; Brzósko S; Pawlak D; Myśliwiec M
    Am J Nephrol; 2004; 24(1):154-61. PubMed ID: 14726627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2007; 120(6):797-803. PubMed ID: 17391740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.